Indolinone derivatives as protein kinase/phosphatase inhibitors

Details Indolinone derivatives as protein kinase/phosphatase inhibitors Indolinone derivatives as protein kinase/phosphatase inhibitors

2006-07-04

2006-07-04

Saeed, Kamal A. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Four or more ring nitrogens in the bicyclo ring system

C544S131000, C546S277700, C548S455000

Reexamination Certificate

active

07071332

ABSTRACT:
The present invention relates to certain 2-indolinone compounds which modulate the activity of protein kinases (“PKs”) and phosphatases. The compounds of this invention are therefore useful in treating disorders related to abnormal PK activity. Pharmaceutical compositions comprising these compounds, methods of treating diseases utilizing pharmaceutical compositions comprising these compounds and methods of preparing them are also disclosed.

REFERENCES:
patent: 2968557 (1961-01-01), Burgandt et al.
patent: 4002749 (1977-01-01), Rovnyak
patent: 4053613 (1977-10-01), Rovnyak et al.
patent: 4642309 (1987-02-01), Michel et al.
patent: 4826847 (1989-05-01), Michel et al.
patent: 5051417 (1991-09-01), Nadler et al.
patent: 5124347 (1992-06-01), Connor et al.
patent: 5196446 (1993-03-01), Levitzki et al.
patent: 5302606 (1994-04-01), Spada et al.
patent: 5322950 (1994-06-01), Sircar et al.
patent: 5374652 (1994-12-01), Buzzetti et al.
patent: 5382593 (1995-01-01), Le Baut et al.
patent: 5389661 (1995-02-01), Sircar et al.
patent: 5397787 (1995-03-01), Buzzetti et al.
patent: 5409949 (1995-04-01), Buzzetti et al.
patent: 5792783 (1998-08-01), Tang et al.
patent: 5834504 (1998-11-01), Tang et al.
patent: 5849710 (1998-12-01), Battistini et al.
patent: 5880141 (1999-03-01), Tang et al.
patent: 5883113 (1999-03-01), Tang et al.
patent: 5883116 (1999-03-01), Tang et al.
patent: 5886020 (1999-03-01), Tang et al.
patent: 6133305 (2000-10-01), Tang et al.
patent: 6531502 (2003-03-01), Tang et al.
patent: 6677368 (2004-01-01), Cui et al.
patent: 6689806 (2004-02-01), Tang et al.
patent: 6797825 (2004-09-01), Lin et al.
patent: 2003/0069297 (2003-04-01), Cui et al.
patent: 2003/0158215 (2003-08-01), Tang et al.
patent: 2004/0097497 (2004-05-01), Tang et al.
patent: 2004/0127544 (2004-07-01), Moon et al.
patent: 2004/0157909 (2004-08-01), Cui et al.
patent: 2004/0204407 (2004-10-01), Tang et al.
patent: 286870 (1967-05-01), None
patent: 2012634 (1991-09-01), None
patent: 2159360 (1973-06-01), None
patent: 2159361 (1973-06-01), None
patent: 2159363 (1973-06-01), None
patent: 2321656 (1973-11-01), None
patent: 3426419 (1986-01-01), None
patent: 0 252 713 (1988-01-01), None
patent: 0 351 213 (1990-01-01), None
patent: 0 525 472 (1993-02-01), None
patent: 0 632 102 (1995-01-01), None
patent: 0 662 473 (1995-07-01), None
patent: 0 769 947 (1997-05-01), None
patent: 0 788 890 (1997-08-01), None
patent: 0 934 931 (1999-08-01), None
patent: 1 082 305 (2001-03-01), None
patent: 1398224 (1965-05-01), None
patent: 1599772 (1970-08-01), None
patent: 2689397 (1993-10-01), None
patent: 809691 (1959-03-01), None
patent: 835473 (1960-05-01), None
patent: 62-29570 (1987-02-01), None
patent: 62-39564 (1987-02-01), None
patent: 63-141955 (1988-06-01), None
patent: 5-58894 (1993-03-01), None
patent: WO 91/13055 (1991-09-01), None
patent: WO 92/07830 (1992-05-01), None
patent: WO 92/20642 (1992-11-01), None
patent: WO 93/01182 (1993-01-01), None
patent: WO 94/14808 (1994-07-01), None
patent: WO 95/01349 (1995-01-01), None
patent: WO 95/17181 (1995-06-01), None
patent: WO 96/00226 (1996-01-01), None
patent: WO 96/16964 (1996-06-01), None
patent: WO 96/22976 (1996-08-01), None
patent: WO 96/32380 (1996-10-01), None
patent: WO 96/40116 (1996-12-01), None
patent: WO 97/25986 (1997-07-01), None
patent: WO 98/07695 (1998-02-01), None
patent: WO 98/24432 (1998-06-01), None
patent: WO 98/38984 (1998-09-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 98/50356 (1998-11-01), None
patent: WO 99/10325 (1999-03-01), None
patent: WO 99/52869 (1999-10-01), None
patent: WO 99/61422 (1999-12-01), None
patent: WO 99/65869 (1999-12-01), None
patent: WO 00/08202 (2000-02-01), None
patent: WO 00/35906 (2000-06-01), None
patent: WO 00/35908 (2000-06-01), None
patent: WO 00/35909 (2000-06-01), None
patent: WO 00/56709 (2000-09-01), None
patent: WO 01/60814 (2001-08-01), None
patent: WO 02/02551 (2002-01-01), None
Lanzi, C. “Inhibition of Transforming Activity of the ret/ptc1 Oncoprotein by a 2-Indolinone Derivative,” Int. J. Cancer, vol. 85, pp. 384-390 (published online Jan. 28 2000), esp. at p. 385, Figure 1, compound 7; also p. 384, col. 2, line 19-22.
Andreani et al., “Potential Antitumor Agents, 25[1 ]. Synthesis and Cytotoxic Activity of 3-(2-Chloro-3-Indolymethylene) 1,3-Dihydroindol-2-Ones,”Anticancer Research16:3585-3588 (1996) © Elsevier, Paris.
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones,”Eur. J. Med. Chem.25:187-190 (1990).
Andreani et al., “Synthesis and cardiotonic activity of 2-indolinones bearing pyridyl groups,”Eur. J. Med. Chem.28:653-657 (1993) © Elsevier, Paris.
Andreani et al., “Synthesis and cardiotonic activity of pyridylmethylene-2-indolinones,”Eur. J. Med. Chem.27:167-170 (1992) © Elsevier, Paris.
Andreani et al., “Synthesis and potential coanthracyclinic activity of substituted 3-(5-imidazo[2,1-b]thiazolylmethylene)-2-indolinones,”Eur. J. Med. Chem.32:919-924 (1997)© Elsevier, Paris.
Andreani et al., “Synthesis of lactams with potential cardiotonic activity,”Eur. J. Med. Chem.28:825-829 (1993).
Andreani et al., “In Vivo Cardiotonic Activity of Pyridylmethylene-2-indolinones,”Arzneimittel-Forschung Drug Research48:727-729 (1998) ©.
Bahner and Brotherton, “6-Dimethylaminochrysene and Other Analogs of 4-(4-Dimethylamino)stilbene,”J. Med. Chem.12:722-723 (1969).
Bahner et al., “Benzylideneindenes with Oxygen Attached to the Indene Ring,”J. Med. Chem.12:721-722 (1969).
Bamfield et al., “Diels-Alder Reactions of Oxindolylideneacetone,”J. Chem. Soc.(C)1028-1030 (1966) ©.
Borsche et al., “Über vielkernige kondensierte Systems mit heterocyclischen Ringen. XIII.,”Liebigs Ann. Chem.550:160-174 (1941).
Buzzetti et al., “Cinnamamide Analogs as Inhibitors of Protein Tyrosine Kinases,”II Farmaco48:615-636 (1993).
Chatten et al., “Substituted Oxindoles. Part VI. Polarographic Reduction of Substitutedtrans-3-Benzylideneindol-2(3H)-ones,”J. Chem. Soc. Perkin II: 469-473 (1973).
Coda et al., “(Z)- and (E)-Arylidene- 1,3-dihydroindol-2-ones: Configuration, Conformation and Infrared Carbonyl Stretching Frequencies,”J. Chem. Soc. Perkin Trans. II: 615-619 (1984).
Coda et al., “3-(4-methylbenzilidene)- 1,3-dihydroindol-2-one,”Journal of the Chemical Society, Perkin Transactions 24:615-620 (1984) Database Crossfire, Beilstein Reference No. 6-21.
Decodts et al., “Suicide inhibitors of proteases. Lack of activity of halomethyl derivatives of some aromatic lactams,”Eur. J. Med. Chem18: 107-111 (1983).
Desimoni et al., “Catalysis with Inorganic Cations. V1Intramolecular Hetero Diels-Alder versus Ene Reactions: Effect of Magnesium perchlorate on Chemoselectivity,”Tetrahedron52(36) 12009-12018 (1196) © Pergamon.
Elliott and Rivers, “Reduction of Some Oxindolylidene Derivatives to 3-Substituted Oxindoles by Sodium Borohydride, ”J. Med. Chem.29:2438-2440 (1964).
Elliott et al., “1-methyl-2-(3-oxindolidenmethyl)-pyridinium,”Journal of Organic Chemistry29:2438-2440 (1964) Database Crossfire, Beilstein Reference No. 5-24.
Gazit et al., “Tyrphostins. 2. Heterocyclic and α-Substituted Benzylidenemalononitrile Tyrphostins as Potent Inhibitors of EGF Receptor and ErbB2
eu Tyrosine Kinases,”J. Med. Chem.34:1896-1907 (1991) copyright Am. Clem. Soc.
Hirao et al., “Rhodium-Catalyzed Carbonylation of 2-Alkynylaniline: Syntheses of 1,3-Dihydroindol-2-ones,”Tetrahedron Letters36(35) 1995 © Pergamon.
Hodges et al., “Chemical and biological properties of some oxindolidyl-3-methines,”Canadian J. Chemistry46:2189-2194 (1968).
Howard, Harry R., “Lactam Derivatives,” U.S. Provisional Appl. No. 60/015,134.
Howard et al., “Synthesis and aldose reductase inhibitory activity of substituted 2(1H)-benzimidazolone- and oxindole-1-ac

Affiliated with

Also associated with

Rating

Indolinone derivatives as protein kinase/phosphatase inhibitors does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Indolinone derivatives as protein kinase/phosphatase inhibitors, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Indolinone derivatives as protein kinase/phosphatase inhibitors will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3574563